127 related articles for article (PubMed ID: 38637094)
21. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features.
Boussen H; Bouzaiene H; Ben Hassouna J; Gamoudi A; Benna F; Rahal K
Semin Oncol; 2008 Feb; 35(1):17-24. PubMed ID: 18308142
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.
Menta A; Fouad TM; Lucci A; Le-Petross H; Stauder MC; Woodward WA; Ueno NT; Lim B
Surg Clin North Am; 2018 Aug; 98(4):787-800. PubMed ID: 30005774
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for locoregional failure in patients with inflammatory breast cancer treated with trimodality therapy.
Saigal K; Hurley J; Takita C; Reis IM; Zhao W; Rodgers SE; Wright JL
Clin Breast Cancer; 2013 Oct; 13(5):335-43. PubMed ID: 23850216
[TBL] [Abstract][Full Text] [Related]
24. Imaging Modalities in Inflammatory Breast Cancer (IBC) Diagnosis: A Computer-Aided Diagnosis System Using Bilateral Mammography Images.
Barkana BD; El-Sayed A; Khaled RH; Helal M; Khaled H; Deeb R; Pitcher M; Pfeiffer R; Roubidoux M; Schairer C; Soliman AS
Sensors (Basel); 2022 Dec; 23(1):. PubMed ID: 36616659
[TBL] [Abstract][Full Text] [Related]
25. Association of inflammatory and noninflammatory breast cancer with socioeconomic characteristics in the Surveillance, Epidemiology, and End Results database, 2000-2007.
Schlichting JA; Soliman AS; Schairer C; Banerjee M; Rozek LS; Schottenfeld D; Harford JB; Merajver SD
Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):155-65. PubMed ID: 22028401
[TBL] [Abstract][Full Text] [Related]
26. Tailoring Treatment for Patients with Inflammatory Breast Cancer.
Newman AB; Lynce F
Curr Treat Options Oncol; 2023 Jun; 24(6):580-593. PubMed ID: 37043118
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory breast cancer in the Netherlands; improved survival over the last decades.
van Uden DJ; Bretveld R; Siesling S; de Wilt JH; Blanken-Peeters CF
Breast Cancer Res Treat; 2017 Apr; 162(2):365-374. PubMed ID: 28138891
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory breast cancer: what we know and what we need to learn.
Yamauchi H; Woodward WA; Valero V; Alvarez RH; Lucci A; Buchholz TA; Iwamoto T; Krishnamurthy S; Yang W; Reuben JM; Hortobágyi GN; Ueno NT
Oncologist; 2012; 17(7):891-9. PubMed ID: 22584436
[TBL] [Abstract][Full Text] [Related]
30. Identifying factors that impact survival among women with inflammatory breast cancer.
Dawood S; Ueno NT; Valero V; Woodward WA; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM; Cristofanilli M
Ann Oncol; 2012 Apr; 23(4):870-5. PubMed ID: 21765048
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Sawaki M; Ito Y; Akiyama F; Tokudome N; Horii R; Mizunuma N; Takahashi S; Horikoshi N; Imai T; Nakao A; Kasumi F; Sakamoto G; Hatake K
Breast Cancer; 2006; 13(2):172-8. PubMed ID: 16755113
[TBL] [Abstract][Full Text] [Related]
32. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory and other breast cancer incidence rate trends by estrogen receptor status in the Surveillance, Epidemiology, and End Results database (2001-2015).
Aurit SJ; Devesa SS; Soliman AS; Schairer C
Breast Cancer Res Treat; 2019 Jun; 175(3):755-764. PubMed ID: 30915662
[TBL] [Abstract][Full Text] [Related]
34. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
[TBL] [Abstract][Full Text] [Related]
35. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
36. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.
Lo AC; Kleer CG; Banerjee M; Omar S; Khaled H; Eissa S; Hablas A; Douglas JA; Alford SH; Merajver SD; Soliman AS
Breast Cancer Res Treat; 2008 Nov; 112(1):141-7. PubMed ID: 18058225
[TBL] [Abstract][Full Text] [Related]
37. Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer.
Rogé M; Kirova Y; Loap P; Amar S; Servagi S; Nebbache R; Rivin Del Campo E; Clatot F; Thureau S; Thariat J
Pract Radiat Oncol; 2023; 13(6):e491-e498. PubMed ID: 37295726
[TBL] [Abstract][Full Text] [Related]
38. Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007).
Zhou Q; Zhang HP; Zhao YT; Wang XH; Xiong W; Liu YJ; Zhang JH;
Chin Med J (Engl); 2020 Nov; 133(21):2552-2557. PubMed ID: 32925286
[TBL] [Abstract][Full Text] [Related]
39. Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
Chainitikun S; Espinosa Fernandez JR; Long JP; Iwase T; Kida K; Wang X; Saleem S; Lim B; Valero V; Ueno NT
PLoS One; 2021; 16(4):e0250057. PubMed ID: 33861773
[TBL] [Abstract][Full Text] [Related]
40. Nomograms for Estimating Cause-Specific Death Rates of Patients With Inflammatory Breast Cancer: A Competing-Risks Analysis.
Xu F; Yang J; Han D; Huang Q; Li C; Zheng S; Wang H; Lyu J
Technol Cancer Res Treat; 2021; 20():15330338211016371. PubMed ID: 34013802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
